

1 **Clinical outcomes and cost-effectiveness of**

2 **COVID-19 vaccination in South Africa**

3

4 Krishna P. Reddy^{1,2,3,*}

5 Kieran P. Fitzmaurice¹

6 Justine A. Scott¹

7 Guy Harling^{4,5,6,7,8}

8 Richard J. Lessells⁹

9 Christopher Panella¹

10 Fatma M. Shebl^{1,3}

11 Kenneth A. Freedberg^{1,3,10,11,12}

12 Mark J. Siedner^{1,3,4,11}

13

14 **Affiliations**

15 ¹ Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, MA, USA

16 ² Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, USA

17 ³ Harvard Medical School, Boston, MA, USA

18 ⁴ Africa Health Research Institute, KwaZulu-Natal, South Africa

19 ⁵ MRC/Wits Rural Public Health & Health Transitions Research Unit (Agincourt), University of the

20 Witwatersrand, South Africa

21 ⁶ School of Nursing & Public Health, College of Health Sciences, University of KwaZulu-Natal, KwaZulu-

22 Natal, South Africa

23 ⁷ Institute for Global Health, University College London, London, UK

24 ⁸ Department of Epidemiology and Harvard Center for Population & Development Studies, Harvard T.H.

25 Chan School of Public Health, Boston, MA, USA

26 ⁹ KwaZulu-Natal Research Innovation and Sequencing (KRISP), College of Health Sciences,

27 University of KwaZulu-Natal, Durban, South Africa

28 ¹⁰ Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA

29 ¹¹ Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

30 ¹² Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston,

31 MA, USA

32

33 ***Corresponding Author**

34 Krishna P. Reddy, MD, MS

35 Medical Practice Evaluation Center

36 Massachusetts General Hospital

37 100 Cambridge Street, Suite 1600

38 Boston, MA 02114

39 USA

40 Phone: +1 617-726-1993

41 Fax: +1 617-726-4120

42 Email: kpreddy@mgh.harvard.edu

43

44 **Keywords:** COVID-19, vaccination, cost-effectiveness, South Africa, resource allocation

45 **Running title:** Cost-effectiveness of COVID-19 vaccination in South Africa

46

47 **ABSTRACT**

48 Low- and middle-income countries are implementing COVID-19 vaccination strategies in light of varying
49 vaccine efficacies and costs, supply shortages, and resource constraints. Here, we use a microsimulation
50 model to evaluate clinical outcomes and cost-effectiveness of a COVID-19 vaccination program in South
51 Africa. We varied vaccination coverage, pace, acceptance, effectiveness, and cost as well as epidemic
52 dynamics. Providing vaccines to at least 40% of the population and prioritizing vaccine rollout prevented
53 >9 million infections and >73,000 deaths and reduced costs due to fewer hospitalizations. Model results
54 were most sensitive to assumptions about epidemic growth and prevalence of prior immunity to SARS-
55 CoV-2, though the vaccination program still provided high value and decreased both deaths and health
56 care costs across a wide range of assumptions. Vaccination program implementation factors, including
57 prompt procurement, distribution, and rollout, are likely more influential than characteristics of the
58 vaccine itself in maximizing public health benefits and economic efficiency.

59

60 INTRODUCTION

61 The development and licensure of COVID-19 vaccines offers a critically important opportunity to curtail
62 the global COVID-19 pandemic.¹⁻⁴ Even before the efficacy and safety of the leading vaccine candidates
63 were established, many high-income countries (HICs) pre-emptively procured stocks of doses in excess
64 of population need.⁵ By contrast, most low- and middle-income countries (LMICs) do not have access to
65 sufficient quantities of vaccine due to cost, limitations in available doses, and logistical challenges of
66 production, distribution, and storage.⁶ Meanwhile, the Africa Centres for Disease Control and Prevention
67 have announced a goal of vaccinating 60% of Africans by the end of 2022.⁷

68
69 There has been much discussion about reported efficacies and costs of different vaccines. However,
70 factors specific to implementation, including vaccine supply, vaccination pace, and acceptance among
71 communities, are increasingly recognized to be crucial to the effectiveness of a vaccination program in
72 promoting epidemic control in HICs – in some cases, even more so than vaccine efficacy.⁸⁻¹¹ How these
73 program implementation factors will affect the clinical and health economic consequences of COVID-19
74 in LMICs has not been well-defined. This is a particularly urgent question given the emergence of SARS-
75 CoV-2 variants, such as B.1.351 in South Africa, that appear to partially reduce efficacy of some
76 vaccines.^{4,12-15}

77
78 In this work, we use a microsimulation model to estimate the clinical and economic outcomes of COVID-
79 19 vaccination programs in South Africa, examining different implementation strategies that
80 policymakers could directly influence. We simulate COVID-19 specific outcomes over 360 days, including
81 daily and cumulative infections (detected and undetected), deaths, years-of-life lost (YLL) attributable to
82 COVID-19 mortality, resource utilization (hospital and intensive care unit [ICU] bed use), and health care
83 costs from the all-payer (public and private) health sector perspective. We examine different strategies

It is made available under a [CC-BY-NC-ND 4.0 International license](#) .

Cost-effectiveness of COVID-19 vaccination in South Africa

84 of vaccination program implementation under multiple scenarios of vaccine effectiveness and epidemic
85 growth, thereby projecting which factors have the greatest impact on clinical and economic outcomes
86 and cost-effectiveness. Our goal was to inform vaccination program priorities in South Africa and other
87 LMICs.

88 **RESULTS**

89 **Clinical and economic benefits of vaccination strategies**

90 To understand the trade-offs inherent to policy decisions regarding the total vaccine supply to purchase
91 and the speed with which to administer vaccinations, we compared the clinical and economic outcomes
92 of different strategies of population coverage (vaccine supply) and vaccination pace. We determined the
93 incremental cost-effectiveness ratio (ICER) of each strategy as the difference in healthcare costs (2020
94 USD) divided by the difference in years-of-life saved (YLS) compared with other strategies of supply and
95 pace. We considered multiple scenarios of epidemic growth, including a scenario in which the effective
96 reproduction number (R_e) varies over time to produce two waves of SARS-CoV-2 infections.

97
98 In both the $R_e=1.4$ scenario and the two-wave epidemic scenario, the absence of a vaccination program
99 resulted in the most infections (~19-21 million) and deaths (70,400-89,300) and highest costs (~\$1.69-
100 1.77 billion) over the 360-day simulation period (Table 1). Vaccinating 40% of the population decreased
101 deaths (82-85% reduction) and resulted in the lowest total health care costs (33-45% reduction) in both
102 scenarios. Increasing the vaccinated population to 67%, the government's target for 2021, decreased
103 deaths and raised costs in both scenarios. Increasing the vaccine supply to 80%, while simultaneously
104 increasing vaccine acceptance to 80%, reduced deaths and raised costs even further in both scenarios. In
105 the $R_e=1.4$ scenario, the 67% supply strategy was less efficient (had a higher ICER) than the 80% supply
106 strategy, and the latter had an ICER of \$4,270/YLS compared with the 40% supply strategy. In the two-
107 wave epidemic scenario, the 67% and 80% supply strategies had ICERs of \$1,990/YLS and \$2,600/YLS. A
108 vaccine supply of 20%, while less efficient than higher vaccine supply levels, still reduced deaths by 72-
109 76% and reduced costs by 15-32% compared with no vaccination. The highest vaccination pace, 300,000
110 vaccinations daily, resulted in the most favorable clinical outcomes and lowest costs compared with
111 lower paces in both the $R_e=1.4$ and the two-wave epidemic scenarios (Table 1).

112

113 Supplementary Table 1 details the differences between a reference vaccination program (supply 67%,
114 pace 150,000 vaccinations/day) and no vaccination program in age-stratified cumulative infections and
115 deaths, hospital and ICU bed use, and health care costs. The reference vaccination program reduced
116 hospital bed-days by 67% and ICU bed-days by 54% compared with no vaccination program.

117

118 When varying both vaccine supply and vaccination pace across different scenarios of epidemic growth
119 (R_e), a faster vaccination pace decreased both COVID-19 deaths and total health care costs, while the
120 impact of a higher vaccine supply on deaths and costs varied (Table 1, Supplementary Table 2). In all
121 four R_e scenarios, a vaccination strategy with supply 40% and pace 300,000/day resulted in fewer deaths
122 and lower costs than a strategy with higher supply (67%) and slower pace (150,000/day). At a
123 vaccination pace of 300,000/day, increasing the vaccine supply from 40% to 67% was cost-saving in the
124 two-wave epidemic scenario, while it resulted in ICERs of \$520/YLS when $R_e=1.4$, \$1,160/YLS when
125 $R_e=1.8$, and \$85,290/YLS when $R_e=1.1$.

126

127 **Sensitivity analysis: vaccine characteristics and alternative scenarios**

128 To understand the influence of extrinsic factors (i.e., those outside the direct control of vaccination
129 program decision makers, such as vaccine effectiveness and costs and epidemic growth), we performed
130 sensitivity analyses in which we varied each of these factors. In each alternative scenario, we projected
131 clinical and economic outcomes and determined the ICER of a reference vaccination program (67%
132 vaccine supply, 150,000 vaccinations/day, similar to stated goals in South Africa) compared with no
133 vaccination program.¹⁶⁻¹⁸

134

135 In one-way sensitivity analysis, the reference vaccination program remained cost-saving compared with
136 a scenario without vaccines across different values of effectiveness against infection, effectiveness
137 against mild/moderate disease, effectiveness against severe/critical disease, and vaccine acceptance
138 (Table 2). When increasing the cost per person vaccinated up to \$25, the vaccination program remained
139 cost-saving. At cost per person vaccinated between \$26 and \$75, the vaccination program increased
140 health care costs compared with a scenario without vaccines, but the ICERs increased only to \$1,500/YLS
141 (Table 2).

142

143 The reference vaccination program had an ICER $< \$100/\text{YLS}$ or was cost-saving compared with a scenario
144 without vaccines across different values of prior immunity (up to 40%), initial prevalence of active
145 COVID-19, reduction in transmission rate among vaccinated but infected individuals, and costs of
146 hospital and ICU care (Table 2, Supplementary Table 3). When there was 50% prior immunity, the
147 vaccination program still reduced deaths but it increased costs, with an ICER of \$22,460/YLS compared
148 with a scenario without vaccines. Notably, when excluding costs of hospital care and ICU care and only
149 considering costs of the vaccination program, the program increased costs, but its ICER compared with
150 no vaccination program was only \$450/YLS (Supplementary Table 3). When several of the main analyses
151 were repeated with lower costs of hospital and ICU care, some ICERs increased, but vaccine supplies of
152 40% or 80% remained non-dominated (with the latter providing greater clinical benefit), while a faster
153 vaccination pace still resulted in greater clinical benefit and lower costs (Supplementary Table 4).

154

155 The influence of different scenarios into which the vaccination program would be introduced on
156 cumulative infections, deaths, and health care costs is depicted in Figure 1. Varying the prevalence of
157 prior immunity and R_e had the greatest influence on both infections and deaths, while varying the cost
158 per person vaccinated had the greatest influence on health care costs. Vaccine effectiveness against

159 infection and effectiveness against severe disease requiring hospitalization were more influential than
160 effectiveness against mild/moderate disease in terms of reductions in deaths and costs.

161

162 **Multi-way sensitivity analyses**

163 In a multi-way sensitivity analysis in which we simultaneously varied vaccine effectiveness against
164 infection and cost per person vaccinated, the reference vaccination program was cost-saving compared
165 with a scenario without vaccines when cost per person vaccinated was \$14.81, even when effectiveness
166 against infection was as low as 20% (Figure 2). When cost per person vaccinated was \$25, the program
167 was cost-saving when effectiveness against infection was at least 40%. Even at the highest examined
168 cost per person vaccinated (\$75) and the lowest examined effectiveness against infection (20%), the
169 vaccination program had an ICER <\$2,000/YLS compared with no vaccination program (Figure 2).

170

171 We performed several additional multi-way sensitivity analyses in which we simultaneously varied
172 combinations of vaccine supply, vaccination pace, vaccine effectiveness against infection, cost per
173 person vaccinated, R_e , and prevalence of prior immunity (Table 3, Supplementary Figs. 4-8). Of note, to
174 optimize efficiency, increasing vaccination pace was more important than increasing vaccine supply. At a
175 cost of \$45 or \$75 per person vaccinated, increasing vaccination pace led to similar or lower ICER
176 (greater economic efficiency), while increasing vaccine supply led to a similar or higher ICER (less
177 economic efficiency) (Supplementary Fig. 4). At a cost up to \$25 per person vaccinated, the vaccination
178 program was cost-saving under nearly all strategies and scenarios (Supplementary Figs. 4-6). Even when
179 the vaccination program increased costs, the ICERs were <\$2,000/YLS compared with a scenario without
180 vaccines (Supplementary Figs. 4-6).

181

182 **DISCUSSION**

183 Using a dynamic COVID-19 microsimulation model, we found that vaccinating 67% of South Africa's
184 population, meeting the government's goal for 2021,¹⁶ would both decrease COVID-19 deaths and
185 reduce overall health care costs compared with a scenario without vaccines or with a 20% vaccine
186 supply, by reducing the number of infections, hospitalizations, and ICU admissions. Further increasing
187 the vaccine supply to 80%, while simultaneously increasing vaccine acceptance, would save even more
188 lives while modestly increasing costs. Vaccination pace – the number of vaccine doses administered
189 daily, rather than supply itself, may be most influential to maximizing public health benefits and
190 economic efficiency. Increasing the pace would reduce both deaths and overall health care costs. The
191 program remained cost-saving even with conservative estimates of vaccine effectiveness and with
192 higher per-person vaccination costs, highlighting that the characteristics of vaccination program
193 implementation are likely to be more influential than the characteristics of the vaccine itself.
194 Furthermore, the vaccination program remained economically efficient (either cost-saving or with a
195 relatively low ICER representing good clinical value for additional money spent) across most epidemic
196 scenarios, including various rates of epidemic growth and a broad range of prevalence of prior
197 population immunity. Though there is no consensus on an ICER threshold for cost-effectiveness in South
198 Africa, for context, the country's gross domestic product per capita in 2019 was approximately \$6,000,
199 and a published South Africa cost-effectiveness threshold from an opportunity cost approach was
200 approximately \$2,950 (2020 US dollars) per disability-adjusted life-year averted.^{19,20}

201

202 Much has been made about differences in the leading vaccine candidates and the impact of variants,
203 such as the B.1.351 (beta) variant which eventually accounted for over 90% of SARS-CoV-2 infections in
204 South Africa and the B.1.617.2 (delta) variant, on vaccine effectiveness.^{4,15} However, we found that,
205 even with substantially lower vaccine efficacy than reported in clinical trials, vaccination programs

206 would prevent the majority of COVID-19 deaths compared to scenarios without vaccines. For example,
207 decreasing vaccine effectiveness against mild/moderate disease and severe/critical disease requiring
208 hospitalization to 40% still reduced COVID-19 deaths by 65,800 (74%) compared with a scenario without
209 vaccines. Although efficacy against symptomatic and severe disease have been the focus of vaccine
210 trials, these parameters were less influential on population-wide health and cost outcomes than efficacy
211 against infection, which is less commonly reported in trials.¹⁻⁴ Nonetheless, the effectiveness ranges we
212 examined in sensitivity analysis include the point estimates of efficacy against symptomatic and severe
213 disease reported in clinical trials of the AstraZeneca ChAdOx1, Moderna mRNA-1273, and Pfizer-
214 BioNTech mRNA BNT162b2 vaccines.¹⁻³ This suggests that all of these vaccines are likely to have both
215 health and economic benefits. Furthermore, our sensitivity analysis examining different R_e scenarios
216 likely captures the potential influence of more contagious SARS-CoV-2 variants such as delta.

217

218 Similarly, we found that vaccination programs remained economically favorable even at relatively high
219 vaccination costs. Though we did not explicitly account for all implementation and scale-up costs of a
220 vaccination program, our estimates of cost per person vaccinated were based on reported costs of both
221 vaccine and delivery in South Africa.²¹⁻²³ Achieving the government's goal of vaccinating 67% of South
222 Africans within one year will depend at least partially on global vaccine supplies and may require global
223 policymakers to better fund and facilitate vaccine distribution and accessible pricing for LMICs, in
224 addition to local attention to delivery infrastructure and community outreach. Although these expenses
225 may increase program costs, we found that the vaccination program would remain cost-saving at a
226 vaccination cost up to \$25/person and likely cost-effective even at per-person vaccination cost up to
227 \$75/person (ICER \$1,500/YLS). This is due to cost offsets in preventing hospitalizations.

228

229 A faster pace of vaccination consistently decreased infections, deaths, and costs across a range of
230 epidemic growth scenarios. Yet, this was not always true of a higher vaccine supply. With lower
231 epidemic growth ($R_e=1.1$), which approximates the basic reproduction number in the intra-wave periods
232 in South Africa, a faster pace remained preferable from a clinical and economic standpoint. But with the
233 faster vaccination pace, increasing the proportion of the population vaccinated from 40% to 67%
234 resulted in higher costs while only modestly reducing years-of-life lost, with an ICER of \$85,290/YLS, well
235 above commonly reported willingness-to-pay thresholds in South Africa.^{20,24–27} By contrast, when a
236 higher epidemic growth rate is seen ($R_e=1.8$), as was documented during the first and second waves in
237 South Africa, a faster vaccination pace remained highly preferable, and increasing the proportion of the
238 population vaccinated from 40% to 67% resulted in fewer years-of-life lost and higher costs with a much
239 lower ICER of \$1,160/YLS. Overall, these results demonstrate the importance of rolling out vaccinations
240 quickly, particularly ahead of any future waves of the epidemic. Consequently, policymakers should
241 invest in establishing a vaccine distribution and administration system to ensure vaccines will be
242 administered as promptly as possible. All available distribution channels, including those in public and
243 private sectors, should be leveraged.

244

245 Our model projections were sensitive to R_e and to the prevalence of prior immunity to SARS-CoV-2.
246 However, vaccination was generally economically efficient even in scenarios of very low epidemic
247 growth, albeit in some instances with a lower supply target. When the prevalence of prior protective
248 immunity was increased to 50%, the ICER rose substantially. We assumed that prior infection protects
249 against another SARS-CoV-2 infection for the duration of the simulation period. If this is not the case,
250 either because immunity wanes or viral variants make prior infection poorly protective against re-
251 infection, as appeared to be seen in the second waves in South Africa and Brazil, then the vaccination
252 program could still provide good value even with a high prevalence of prior infection.^{28,29}

253

254 These results should be interpreted within the context of several limitations. We assumed that vaccine
255 effectiveness was constant starting 14 days after administration and continuing throughout the 360-day
256 simulation. Early data suggest that post-vaccination immunity lasts at least for months.^{1-3,30,31} Our model
257 assumes homogeneous mixing of the entire population. This assumption may result in conservative
258 estimates of cost-effectiveness of vaccination, particularly at lower supply levels, because herd
259 immunity is likely to be achieved at lower rates of vaccination after accounting for heterogeneous
260 mixing.³² There may be economies of scale such that the cost per person vaccinated decreases as the
261 vaccine supply or vaccination pace increase and vaccination program resources are used more
262 efficiently. Our modeled vaccination prioritization was based exclusively on age and not on employment
263 type, comorbidity presence, or urban/rural heterogeneity in epidemiology or vaccination delivery.
264 Vaccination programs that reach vulnerable and disadvantaged groups would likely improve population-
265 level health outcomes and health equity. Long-term disability among some of those who recover from
266 COVID-19 is an important consideration for policymakers not captured by our model, which considers
267 only years-of-life lost due to premature mortality. Our vaccination cost-effectiveness results may
268 therefore be conservative, particularly among younger age groups that are less likely to die from COVID-
269 19 but are still at risk for long-term sequelae.³³ We did not consider the impact of COVID-19 or
270 vaccination on other health care programs (e.g., HIV and tuberculosis care). We assessed costs from a
271 health care sector perspective and did not account for other sector costs associated with lockdowns and
272 failure to achieve epidemic suppression (e.g., macroeconomic factors such as job and productivity losses
273 and microeconomic factors such as reduced household income and disruptions to education).^{34,35}
274 Excluding these costs may underestimate the true value of COVID-19 vaccination to society. We did not
275 explicitly model the use of non-pharmaceutical interventions (NPIs) as a standalone strategy or in
276 combination with vaccination. However, the evaluation of various transmission scenarios (including a

277 sensitivity analysis in which R_0 changes over time) captures the potential impacts of different levels of
278 NPI implementation on clinical outcomes. As with all modeling exercises, our results are contingent on
279 assumptions and input parameters. Primary assumptions in our model included initial prevalence of
280 COVID-19, prevalence of prior immunity, time to vaccine rollout, and vaccine efficacy against
281 asymptomatic infection.

282

283 Given data limitations and the uncertainty in making long-term projections, we limited the time horizon
284 of our analysis to one year. The sustainability and cost-effectiveness of vaccination beyond one year is
285 likely to depend on the duration of protection conferred by existing vaccines, their effectiveness against
286 emergent variants, and the costs, effectiveness, and frequency of potential booster shots—factors
287 which remain unknown as of June 2021. If SARS-CoV-2 becomes endemic, cost-effectiveness analysis
288 will become increasingly critical for integrating vaccination programs within health program budgets.

289

290 In summary, we found that a COVID-19 vaccination program would reduce infections and deaths and
291 likely reduce overall health care costs in South Africa across a range of possible scenarios, even with
292 conservative assumptions around vaccine effectiveness. Our model simulations underscore that in South
293 Africa and similar settings, acquisition and rapid distribution of vaccines should be prioritized over
294 relatively small differences in vaccine effectiveness and price. The pace of vaccination is as or more
295 important than population coverage, and therefore attention to vaccination program infrastructure is
296 critical. Non-pharmaceutical practices such as mask wearing and physical distancing remain crucial to
297 reduce epidemic growth while vaccination programs are being implemented.¹⁰ Policymakers can use our
298 results to guide decisions about vaccine selection, supply, and distribution to maximally reduce the
299 deleterious impact of the COVID-19 pandemic in South Africa.

300

301 **METHODS**

302 **Analytic overview**

303 We used the Clinical and Economic Analysis of COVID-19 Interventions (CEACOV) dynamic state-
304 transition Monte Carlo microsimulation model to reflect COVID-19 natural history, vaccination, and
305 treatment.³⁶ We previously used the CEACOV model to project COVID-19 clinical and economic
306 outcomes in a variety of settings, including an analysis of non-pharmaceutical public health
307 interventions in South Africa.^{24,37–39}

308

309 Starting with SARS-CoV-2 active infection prevalence of 0.1% (or approximately 60,000 active cases,
310 roughly 10 times the number reported in the first 10 days of April 2021), we projected clinical and
311 economic outcomes over 360 days, including daily and cumulative infections, deaths, hospital and ICU
312 bed use, and health care costs without discounting.⁴⁰ Outside the model, we calculated the mean
313 lifetime years-of-life saved (YLS) from each averted COVID-19 death during the 360-day model horizon,
314 stratified by age (mean 17.77 YLS per averted COVID-19 death across all individuals, Supplementary
315 Methods). We did not include costs beyond the 360-day model horizon.²⁴ We determined the
316 incremental cost-effectiveness ratio (ICER), the difference in health care costs (2020 US dollars) divided
317 by the difference in life-years between different vaccination strategies. Our ICER estimates include
318 health care costs during the 360-day model horizon and YLS over a lifetime from averted COVID-19
319 deaths during the 360-day model horizon.²⁴ “Cost-saving” strategies were those resulting in higher
320 clinical benefits (fewer life-years lost) and lower costs than an alternative.

321

322

323

324

325 **Model structure**

326 In each simulation, we assumed a fixed supply of vaccine that would be administered to eligible and
327 willing individuals regardless of history of SARS-CoV-2 infection. Available vaccine doses would first be
328 offered to those aged ≥ 60 years, then to those aged 20-59 years, and finally to those aged < 20 years.⁴¹

329

330 In the base case, we applied characteristics of Ad26.COV2.S (Johnson & Johnson/Janssen), a single-dose
331 vaccine for which administration in South Africa began through a phase 3b study in health care workers
332 in February 2021.^{4,42} To reflect possible implementation of other vaccines, as well as published data and
333 uncertainties around the type of protection provided by each vaccine, we varied vaccine effectiveness
334 against SARS-CoV-2 infection, effectiveness against mild/moderate COVID-19 disease, and effectiveness
335 against severe COVID-19 disease requiring hospitalization. We assumed that a single vaccine dose would
336 be given and did not explicitly model a two-dose schedule.

337

338 At model initiation, each individual is either susceptible to SARS-CoV-2, infected with SARS-CoV-2, or
339 immune (by way of prior infection). Each susceptible individual faces a daily probability of SARS-CoV-2
340 infection. Once infected, an individual moves to the pre-infectious latency state and faces age-
341 dependent probabilities of developing asymptomatic, mild/moderate, severe, or critical disease
342 (Supplementary Methods, Supplementary Table 5, Supplementary Fig. 1). Individuals with severe or
343 critical disease are referred to hospitals and ICUs, respectively. If hospital/ICU bed capacity has been
344 reached, the individual receives the next lower available intervention, which is associated with different
345 mortality risk and cost (e.g., if a person needs ICU care when no ICU beds are available, they receive
346 non-ICU hospital care). Details of COVID-19 transmission, natural history, and hospital care in the model
347 are described elsewhere and in the Supplementary Methods.²⁴

348

349 **Input parameters**

350 We defined the age distribution based on 2019 South Africa population estimates, in which 37% were
351 aged <20 years, 54% were 20-59 years, and 9% were ≥ 60 years (Table 3).⁴³ We assumed in the base case
352 that, at model initiation, 30% had prior infection and were immune to repeat infection. This assumption
353 was based on an estimate of the proportion of South Africa's population that had been exposed to the
354 B.1.351 variant by 30 January 2021 (Supplementary Methods).^{15,44-46}

355
356 In the reference vaccination program strategy we assumed: a) there would be a sufficient supply of
357 vaccine doses to fully vaccinate 67% of South Africa's population (approximately 40 million vaccinated
358 people);¹⁶ b) pace of vaccination was 150,000 doses/day.^{17,18} Our comparisons of different vaccination
359 program strategies included varying the vaccine supply to that sufficient to cover 0-80% of South Africa's
360 population and increasing the pace of vaccination up to 300,000 doses/day. In the base case, we
361 assumed that vaccine uptake among those eligible was 67%, accounting for vaccine hesitancy and failure
362 to reach some individuals.^{47,48} Vaccine effectiveness was 40% against infection, 51% against
363 mild/moderate disease, and 86% against severe or critical disease requiring hospitalization. The latter
364 two were based on reported efficacies of the Johnson & Johnson/Janssen vaccine ≥ 14 days post-
365 vaccination in South Africa.⁴

366
367 Supplementary Table 5 indicates daily disease progression probabilities, age-dependent probabilities of
368 developing severe or critical disease, and age-dependent mortality probabilities for those with critical
369 disease. We stratified transmission rates by disease state, adjusting them to reflect an initial effective
370 reproduction number (R_e)=1.4 in the base case.⁴⁹ We also simulated alternative epidemic growth
371 scenarios with lower or higher initial R_e and a scenario in which there were episodic surges above a

372 lower background basic reproduction number (R_0), as observed in the South Africa epidemic over the
373 past year (Supplementary Methods).

374

375 The maximum availability of hospital and ICU beds per day was 119,400 and 3,300 (Table 3).⁵⁰ We
376 applied vaccination costs and daily costs of hospital care and ICU care based on published estimates
377 and/or cost quotes obtained in South Africa (Table 3 and Supplementary Methods). In the base case, we
378 applied a total vaccination cost of \$14.81 per person, based on estimated costs in South Africa of
379 \$10/dose for the vaccine and \$4.81/dose for service and delivery (Supplementary Methods).^{21–23} We
380 varied vaccination costs in sensitivity analyses.

381

382 **Validation**

383 We previously validated our natural history assumptions by comparing model-projected COVID-19
384 deaths with those reported in South Africa.²⁴ We updated our validation by comparing the model-
385 projected number of COVID-19 infections and deaths with the number of cases and deaths reported in
386 South Africa through 10 April 2021, accounting for underreporting (Supplementary Methods,
387 Supplementary Fig. 3).^{40,51}

388

389 **Sensitivity analysis**

390 We used sensitivity analysis to examine the relative influence on clinical and cost projections of various
391 parameters around vaccine characteristics and epidemic growth (Table 3). Specifically, we varied:
392 vaccine acceptance (50-90% among eligible individuals); vaccine effectiveness in preventing infection
393 (20-75%), mild/moderate disease (29-79%), and severe/critical disease requiring hospitalization (40-
394 98%); cost (\$9-75/person); initial prevalence of COVID-19 disease (0.05-0.5%); initial R_e (1.1-1.8); prior
395 immunity (10-50% of population); reduction in transmission rate among vaccinated but infected

396 individuals (0-50%); and hospital and ICU daily costs (0.5x-2.0x base case costs). The ranges of vaccine
397 effectiveness against mild/moderate disease and severe/critical disease requiring hospitalization were
398 based on efficacies and 95% confidence intervals reported in the Johnson & Johnson/Janssen vaccine
399 trial (Supplementary Methods).⁴ We also examined ICERs when the relatively high costs of ICU care were
400 excluded and when all hospital care costs (non-ICU and ICU) were excluded. We performed multi-way
401 sensitivity analyses in which we simultaneously varied parameters influential in one-way sensitivity
402 analyses.
403

404 **DATA AVAILABILITY**

405 This modeling study involved the use of published or publicly available data. The data used and the
406 sources are described in the Manuscript and Supplementary Information. No primary data were
407 collected for this study. Model flowcharts are in the Supplementary Information.

408

409 **CODE AVAILABILITY**

410 The simulation model code is available at <https://zenodo.org/record/5565320>

411 (doi:10.5281/zenodo.5565320).

412

413 **REFERENCES**

- 414 1. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-
415 2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet*
416 **397**, 99–111 (2021).
- 417 2. Polack, F. P. *et al.* Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. *N Engl J Med* **383**,
418 2603–2615 (2020).
- 419 3. Baden, L. R. *et al.* Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* **384**, 403–
420 416 (2021).
- 421 4. Sadoff, J. *et al.* Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. *N Engl J*
422 *Med* **384**, 2187–2201 (2021).
- 423 5. Torjesen, I. Covid-19: Pre-purchasing vaccine—sensible or selfish? *BMJ* **370**, m3226 (2020).
- 424 6. Nkengasong, J. N., Ndembi, N., Tshangela, A. & Raji, T. COVID-19 vaccines: how to ensure Africa has
425 access. *Nature* **586**, 197–199 (2020).
- 426 7. Reuters Staff. Africa foresees 60% of people vaccinated against COVID in two to three years. *Reuters*
427 <https://www.reuters.com/article/us-health-coronavirus-africa-idUSKBN28D1D3> (2020).
- 428 8. Paltiel, A. D., Schwartz, J. L., Zheng, A. & Walensky, R. P. Clinical outcomes of a COVID-19 vaccine:
429 implementation over efficacy. *Health Aff (Millwood)* **40**, 42–52 (2021).
- 430 9. Paltiel, A. D., Zheng, A. & Schwartz, J. L. Speed versus efficacy: quantifying potential tradeoffs in
431 COVID-19 vaccine deployment. *Ann Intern Med* (2021).
- 432 10. Giordano, G. *et al.* Modeling vaccination rollouts, SARS-CoV-2 variants and the requirement for non-
433 pharmaceutical interventions in Italy. *Nat Med* **27**, 993–998 (2021).
- 434 11. Sah, P. *et al.* Accelerated vaccine rollout is imperative to mitigate highly transmissible COVID-19
435 variants. *EClinicalMedicine* **35**, 100865 (2021).
- 436 12. Liu, Y. *et al.* Neutralizing activity of BNT162b2-elicited serum. *N Engl J Med* **384**, 1466–1468 (2021).

- 437 13. Madhi, S. A. *et al.* Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant. *N*
438 *Engl J Med* **384**, 1885–1898 (2021).
- 439 14. Shinde, V. *et al.* Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B. 1.351 Variant. *N Engl J*
440 *Med* **384**, 1899–1909 (2021).
- 441 15. Tegally, H. *et al.* Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* **592**, 438–443
442 (2021).
- 443 16. COVID-19 Coronavirus vaccine strategy | South African Government. [https://www.gov.za/covid-](https://www.gov.za/covid-19/vaccine/strategy)
444 [19/vaccine/strategy](https://www.gov.za/covid-19/vaccine/strategy) (2021).
- 445 17. Parliament of the Republic of South Africa. Portfolio Committee on Health’s Zoom Meeting, 7
446 January 2021. https://www.youtube.com/watch?v=jTZfp__pykY (2021).
- 447 18. Matiwane, Z. Covid-19 vaccine rollout: 200,000-a-day jabs plan unveiled. *TimesLIVE*
448 [https://www.timeslive.co.za/sunday-times/news/2021-03-28-covid-19-vaccine-rollout-200000-a-](https://www.timeslive.co.za/sunday-times/news/2021-03-28-covid-19-vaccine-rollout-200000-a-day-jabs-plan-unveiled/)
449 [day-jabs-plan-unveiled/](https://www.timeslive.co.za/sunday-times/news/2021-03-28-covid-19-vaccine-rollout-200000-a-day-jabs-plan-unveiled/) (2021).
- 450 19. The World Bank. GDP per capita (current US\$) - South Africa.
451 <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=ZA> (2021).
- 452 20. Edoaka, I. P. & Stacey, N. K. Estimating a cost-effectiveness threshold for health care decision-making
453 in South Africa. *Health Policy Plan* **35**, 546–555 (2020).
- 454 21. Reuters Staff. J&J, African Union in deal for up to 400 million COVID-19 shots. *Reuters*
455 <https://www.reuters.com/article/uk-health-coronavirus-j-j-vaccine-idUSKBN2BL1V4> (2021).
- 456 22. Business Insider South Africa. SA is the first country to roll out Johnson & Johnson vaccine - what
457 you need to know about the jab. [https://www.businessinsider.co.za/covid-19-vaccine-johnson-](https://www.businessinsider.co.za/covid-19-vaccine-johnson-johnson-what-we-know-2020-12)
458 [johnson-what-we-know-2020-12](https://www.businessinsider.co.za/covid-19-vaccine-johnson-johnson-what-we-know-2020-12) (2021).
- 459 23. Moodley, I., Tathiah, N. & Sartorius, B. The costs of delivering human papillomavirus vaccination to
460 Grade 4 learners in KwaZulu-Natal, South Africa. *S Afr Med J* **106**, 497–501 (2016).

- 461 24. Reddy, K. P. *et al.* Cost-effectiveness of public health strategies for COVID-19 epidemic control in
462 South Africa: a microsimulation modelling study. *Lancet Glob Health* **9**, e120–e129 (2021).
- 463 25. Reddy, K. P. *et al.* Cost-effectiveness of urine-based tuberculosis screening in hospitalised patients
464 with HIV in Africa: a microsimulation modelling study. *Lancet Glob Health* **7**, e200–e208 (2019).
- 465 26. Woods, B., Revill, P., Sculpher, M. & Claxton, K. Country-level cost-effectiveness thresholds: initial
466 estimates and the need for further research. *Value Health* **19**, 929–935 (2016).
- 467 27. Meyer-Rath, G., van Rensburg, C., Larson, B., Jamieson, L. & Rosen, S. Revealed willingness-to-pay
468 versus standard cost-effectiveness thresholds: evidence from the South African HIV Investment
469 Case. *PLoS One* **12**, e0186496 (2017).
- 470 28. Sabino, E. C. *et al.* Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence. *Lancet*
471 **397**, 452–455 (2021).
- 472 29. Cele, S. *et al.* Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. *Nature*
473 **593**, 142–146 (2021).
- 474 30. Widge, A. T. *et al.* Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. *N Engl J Med*
475 **384**, 80–82 (2021).
- 476 31. Doria-Rose, N. *et al.* Antibody persistence through 6 months after the second dose of mRNA-1273
477 vaccine for Covid-19. *N Engl J Med* **384**, 2259–2261 (2021).
- 478 32. Britton, T., Ball, F. & Trapman, P. A mathematical model reveals the influence of population
479 heterogeneity on herd immunity to SARS-CoV-2. *Science* **369**, 846–849 (2020).
- 480 33. Briggs, A. & Vassall, A. Count the cost of disability caused by COVID-19. *Nature* **593**, 502–505 (2021).
- 481 34. Statistics South Africa. Quarterly Labour Force Survey. Quarter 4: 2020.
482 <http://www.statssa.gov.za/publications/P0211/P02114thQuarter2020.pdf> (2021).
- 483 35. National Treasury, Republic of South Africa. Budget Review.
484 <http://www.treasury.gov.za/documents/national%20budget/2021/review/FullBR.pdf> (2021).

- 485 36. Panella, C. & Talbot, V.R. Cost-effectiveness of COVID-19 vaccination in South Africa. CEACOV v0.8.
486 Available at <https://zenodo.org/record/5565320>, doi:10.5281/zenodo.5565320 (2021).
- 487 37. Neilan, A. M. *et al.* Clinical impact, costs, and cost-effectiveness of expanded SARS-CoV-2 testing in
488 Massachusetts. *Clin Infect Dis* (2020).
- 489 38. Baggett, T. P. *et al.* Clinical outcomes, costs, and cost-effectiveness of strategies for adults
490 experiencing sheltered homelessness during the COVID-19 pandemic. *JAMA Netw Open* **3**,
491 e2028195 (2020).
- 492 39. Losina, E. *et al.* College campuses and COVID-19 mitigation: clinical and economic value. *Ann Intern*
493 *Med* **174**, 472–483 (2020).
- 494 40. National Institute for Communicable Diseases. National COVID-19 Daily Report.
495 [https://www.nicd.ac.za/diseases-a-z-index/covid-19/surveillance-reports/national-covid-19-daily-](https://www.nicd.ac.za/diseases-a-z-index/covid-19/surveillance-reports/national-covid-19-daily-report/)
496 [report/](https://www.nicd.ac.za/diseases-a-z-index/covid-19/surveillance-reports/national-covid-19-daily-report/) (2021).
- 497 41. Pfizer. Pfizer-BioNTech announce positive topline results of pivotal COVID-19 vaccine study in
498 adolescents. [https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal)
499 [announce-positive-topline-results-pivotal](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-biontech-announce-positive-topline-results-pivotal) (2021).
- 500 42. Arthur, R. South Africa starts administering Janssen COVID-19 vaccine to health workers.
501 *biopharma-reporter.com* [https://www.biopharma-reporter.com/Article/2021/02/18/South-Africa-](https://www.biopharma-reporter.com/Article/2021/02/18/South-Africa-starts-administering-Janssen-COVID-19-vaccine-to-health-workers)
502 [starts-administering-Janssen-COVID-19-vaccine-to-health-workers](https://www.biopharma-reporter.com/Article/2021/02/18/South-Africa-starts-administering-Janssen-COVID-19-vaccine-to-health-workers) (2021).
- 503 43. Statistics South Africa. Mid-year population estimates 2019.
504 <https://www.statssa.gov.za/publications/P0302/P03022019.pdf> (2019).
- 505 44. National Institute for Communicable Diseases. *COVID-19 Weekly Epidemiology Brief - Week 4, 2021.*
506 [https://www.nicd.ac.za/diseases-a-z-index/covid-19/surveillance-reports/weekly-epidemiological-](https://www.nicd.ac.za/diseases-a-z-index/covid-19/surveillance-reports/weekly-epidemiological-brief/)
507 [brief/](https://www.nicd.ac.za/diseases-a-z-index/covid-19/surveillance-reports/weekly-epidemiological-brief/).

- 508 45. Sykes, W. *et al.* Prevalence of anti-SARS-CoV-2 antibodies among blood donors in Northern Cape,
509 KwaZulu-Natal, Eastern Cape, and Free State provinces of South Africa in January 2021. Preprint at
510 doi:10.21203/rs.3.rs-233375/v1 (2021).
- 511 46. National Institute for Communicable Diseases. *COVID-19 Weekly Epidemiology Brief - Week 46,*
512 *2020.* [https://www.nicd.ac.za/wp-content/uploads/2020/11/COVID-19-Weekly-Epidemiology-Brief-](https://www.nicd.ac.za/wp-content/uploads/2020/11/COVID-19-Weekly-Epidemiology-Brief-week-46.pdf)
513 [week-46.pdf](https://www.nicd.ac.za/wp-content/uploads/2020/11/COVID-19-Weekly-Epidemiology-Brief-week-46.pdf) (2020).
- 514 47. Larson, H. J. *et al.* The state of vaccine confidence 2016: global insights through a 67-country survey.
515 *EBioMedicine* **12**, 295–301 (2016).
- 516 48. Runciman, C., Roberts, B., Alexander, K., Bohler-Muller, N. & Bekker, M. UJ-HSRC Covid-19
517 Democracy Survey. Willingness to take a Covid-19 vaccine: A research briefing.
518 [http://www.hsrc.ac.za/uploads/pageContent/1045085/2021-01-](http://www.hsrc.ac.za/uploads/pageContent/1045085/2021-01-25%20Vaccine%20briefing%20(final).pdf)
519 [25%20Vaccine%20briefing%20\(final\).pdf](http://www.hsrc.ac.za/uploads/pageContent/1045085/2021-01-25%20Vaccine%20briefing%20(final).pdf) (2021).
- 520 49. Covid-19: Estimates for South Africa. *Covid-19* [https://epiforecasts.io/covid/posts/national/south-](https://epiforecasts.io/covid/posts/national/south-africa/)
521 [africa/](https://epiforecasts.io/covid/posts/national/south-africa/) (2020).
- 522 50. COVID-19 Public Health Response - SA Corona Virus Online Portal. *SA Corona Virus Online Portal*
523 <https://sacoronavirus.co.za/2020/04/11/covid-19-public-health-response/> (2020).
- 524 51. National Institute for Communicable Diseases. COVID-19 Weekly Hospital Surveillance Update -
525 Week 14, 2021. [https://www.nicd.ac.za/wp-content/uploads/2021/04/NICD-COVID-19-Weekly-](https://www.nicd.ac.za/wp-content/uploads/2021/04/NICD-COVID-19-Weekly-Hospital-Surveillance-update-Week-14-2021.pdf)
526 [Hospital-Surveillance-update-Week-14-2021.pdf](https://www.nicd.ac.za/wp-content/uploads/2021/04/NICD-COVID-19-Weekly-Hospital-Surveillance-update-Week-14-2021.pdf) (2021).
- 527 52. Netcare Hospitals. 2019 Tariffs. [https://www.netcarehospitals.co.za/Portals/3/Images/Content-](https://www.netcarehospitals.co.za/Portals/3/Images/Content-images/PDF/2019-Private-Paying-Patients.pdf)
528 [images/PDF/2019-Private-Paying-Patients.pdf](https://www.netcarehospitals.co.za/Portals/3/Images/Content-images/PDF/2019-Private-Paying-Patients.pdf) (2019).
- 529 53. Edoka, I., Fraser, H., Jamieson, L., Meyer-Rath, G. & Mdewa, W. Inpatient care costs of COVID-19 in
530 South Africa's public healthcare system. *International Journal of Health Policy and Management*
531 (2021).

- 532 54. Consumer Price Index: All Items for South Africa. *FRED, Federal Reserve Bank of St. Louis*
- 533 <https://fred.stlouisfed.org/series/ZAFCPALLMINMEI> (2021).
- 534 55. South Africa / U.S. Foreign Exchange Rate. *FRED, Federal Reserve Bank of St. Louis*
- 535 <https://fred.stlouisfed.org/series/DEXSFUS> (2021).
- 536 56. Mahomed, S. & Mahomed, O. H. Cost of intensive care services at a central hospital in South Africa.
- 537 *S Afr Med J* **109**, 35–39 (2019).
- 538

539 **ACKNOWLEDGEMENTS**

540 This research was supported by the National Institute of Allergy and Infectious Diseases of the National
541 Institutes of Health [R37 AI058736-16S1] (KAF) and by the Wellcome Trust [Grant number
542 210479/Z/18/Z] (GH). For the purpose of open access, the author has applied a CC BY public copyright
543 license to any Author Accepted Manuscript version arising from this submission.

544

545 The funding sources had no role in the study design, data collection, data analysis, data interpretation,
546 writing of the manuscript, or in the decision to submit the manuscript for publication. The content is
547 solely the responsibility of the authors and does not necessarily represent the official views of the
548 funding sources.

549

550 The authors thank Nattanicha Wattananimitgul, Eli Schwamm, and Nora Mulroy for technical assistance.

551

552 **AUTHOR CONTRIBUTIONS**

553 All authors contributed substantively to this manuscript in the following ways: study and model design
554 (KPR, KPF, JAS, GH, RJL, CP, FMS, KAF, MJS), data analysis (KPR, KPF, JAS, FMS, KAF, MJS), interpretation
555 of results (KPR, KPF, JAS, GH, RJL, CP, FMS, KAF, MJS), drafting the manuscript (KPR, MJS), critical
556 revision of the manuscript (KPR, KPF, JAS, GH, RJL, CP, FMS, KAF, MJS) and final approval of the
557 submitted version (KPR, KPF, JAS, GH, RJL, CP, FMS, KAF, MJS).

558

559 **COMPETING INTERESTS**

560 RJL serves on South Africa's Ministerial Advisory Committee on COVID-19 Vaccines (VMAC). We declare
561 no additional competing interests.

562 **Table 1. Clinical and economic outcomes of different COVID-19 vaccination program strategies of vaccine supply and vaccination pace under**
 563 **different scenarios of epidemic growth in South Africa.**

Scenario and Vaccination Strategy	Cumulative SARS-CoV-2 infections	Cumulative COVID-19 deaths	Years-of-life lost	Health care costs, USD	ICER, USD per year-of-life saved ^a
Vaccine supply					
<i>R_e = 1.4</i>					
Vaccine supply 40%	11,784,700	16,000	275,800	1,177,742,900	--
Vaccine supply 67%	10,585,100	14,700	259,600	1,338,803,500	Dominated
Vaccine supply 80% ^b	10,410,000	12,000	217,900	1,425,272,800	4,270
Vaccine supply 20%	15,489,500	21,800	397,300	1,508,890,800	Dominated
No vaccination	21,012,100	89,300	1,558,700	1,766,856,200	Dominated
<i>Two-wave epidemic^c</i>					
Vaccine supply 40%	7,758,800	10,600	175,100	927,247,000	--
Vaccine supply 67%	5,594,000	7,800	133,700	1,009,741,300	1,990
Vaccine supply 80% ^b	5,940,500	6,900	119,100	1,047,885,500	2,600
Vaccine supply 20%	12,765,900	19,900	371,500	1,148,772,700	Dominated
No vaccination	19,290,400	70,400	1,206,200	1,691,805,000	Dominated
Vaccination pace					
<i>R_e = 1.4</i>					
Pace 300,000 vaccinations per day	5,659,400	7,200	120,300	1,016,586,100	--
Pace 200,000 vaccinations per day	8,191,900	9,600	151,300	1,123,694,300	Dominated
Pace 150,000 vaccinations per day	10,585,100	14,700	259,600	1,338,803,500	Dominated
No vaccination	21,012,100	89,300	1,558,700	1,766,856,200	Dominated
<i>Two-wave epidemic^c</i>					
Pace 300,000 vaccinations per day	2,697,100	3,200	49,300	780,133,600	--
Pace 200,000 vaccinations per day	4,148,500	5,900	90,300	881,291,000	Dominated
Pace 150,000 vaccinations per day	5,594,000	7,800	133,700	1,009,741,300	Dominated
No vaccination	19,290,400	70,400	1,206,200	1,691,805,000	Dominated
Vaccine supply and vaccination pace					
<i>R_e = 1.4</i>					
Vaccine supply 40%, pace 300,000 vaccinations per day	9,866,800	13,000	211,300	969,576,100	--
Vaccine supply 67%, pace 300,000 vaccinations per day	5,659,400	7,200	120,300	1,016,586,100	520

Vaccine supply 40%, pace 150,000 vaccinations per day	11,784,700	16,000	275,800	1,177,742,900	Dominated
Vaccine supply 67%, pace 150,000 vaccinations per day	10,585,100	14,700	259,600	1,338,803,500	Dominated
No vaccination	21,012,100	89,300	1,558,700	1,766,856,200	Dominated
Two-wave epidemic ^c					
Vaccine supply 67%, pace 300,000 vaccinations per day	2,697,100	3,200	49,300	780,133,600	--
Vaccine supply 40%, pace 300,000 vaccinations per day	6,223,600	7,200	126,900	780,274,900	Dominated
Vaccine supply 40%, pace 150,000 vaccinations per day	7,758,800	10,600	175,100	927,247,000	Dominated
Vaccine supply 67%, pace 150,000 vaccinations per day	5,594,000	7,800	133,700	1,009,741,300	Dominated
No vaccination	19,290,400	70,400	1,206,200	1,691,805,000	Dominated

564 USD: United States dollars. ICER: incremental cost-effectiveness ratio. R_e : effective reproduction number. Dominated: the strategy results in a
 565 higher ICER than that of a more clinically effective strategy, or the strategy results in less clinical benefit (more years-of-life lost) and higher
 566 health care costs than an alternative strategy.

567

568 ^aWithin each R_e scenario, vaccination strategies are ordered from lowest to highest cost per convention of cost-effectiveness analysis. ICERs are
 569 calculated compared to the next least expensive, non-dominated strategy. Displayed life-years and costs are rounded to the nearest hundred,
 570 while ICERs are calculated based on non-rounded life-years and costs and then rounded to the nearest ten.

571

572 ^bWhen modeling a vaccination program that seeks to vaccinate 80% of the population, uptake among those eligible was increased to 80% to
 573 avoid a scenario in which supply exceeds uptake. If uptake is not increased beyond 67%, then the strategy of vaccinating 67% of the population
 574 provides the most clinical benefit and results in an ICER of \$9,960/YLS compared with vaccinating 40% of the population when R_e is 1.4 and
 575 \$1,990/YLS in an epidemic scenario with periodic surges.

576

577 ^cIn the analysis of an epidemic with periodic surges, the basic reproduction number (R_0) alternates between low and high values over time, and
 578 the R_e changes day-to-day as the epidemic and vaccination program progress and there are fewer susceptible individuals. For most of the
 579 simulation horizon, R_0 is 1.6 (equivalent to an initial R_e of 1.1). However, during days 90-150 and 240-300 of the simulation, R_0 is increased to 2.6.
 580 This results in two epidemic waves with peak R_e of approximately 1.4-1.5.

581

582

583 **Table 2. One-way sensitivity analyses of different COVID-19 vaccine characteristic and epidemic**
 584 **growth scenarios in South Africa.**
 585

Parameter / Value	SARS-CoV-2 infections averted, compared with no vaccination	COVID-19 deaths averted, compared with no vaccination	Years-of-life saved, compared with no vaccination	Change in health care costs, compared with no vaccination, USD	ICER, compared with no vaccination, USD per YLS ^a
Vaccine effectiveness in preventing SARS-CoV-2 infection, %					
20	5,466,500	71,600	1,254,900	-166,032,500	Cost-saving
40 (base case)	10,427,000	74,600	1,299,100	-428,052,700	Cost-saving
50	12,758,000	77,500	1,349,700	-554,501,500	Cost-saving
75 ^b	16,067,300	82,000	1,429,400	-750,946,700	Cost-saving
Vaccine effectiveness in preventing mild/moderate COVID-19, % ^c					
29	8,310,500	74,000	1,298,900	-377,101,700	Cost-saving
51 (base case)	10,427,000	74,600	1,299,100	-428,052,700	Cost-saving
67	10,625,200	76,200	1,332,200	-410,883,200	Cost-saving
79	10,722,500	75,300	1,316,800	-399,131,600	Cost-saving
Vaccine effectiveness in preventing severe or critical COVID-19 requiring hospitalization, % ^d					
40	10,659,300	65,800	1,180,100	-80,901,300	Cost-saving
86 (base case)	10,427,000	74,600	1,299,100	-428,052,700	Cost-saving
98	10,690,200	77,500	1,341,700	-545,358,200	Cost-saving
Vaccine acceptance among those eligible, %					
50	10,026,700	71,100	1,251,600	-272,592,000	Cost-saving
67 (base case)	10,427,000	74,600	1,299,100	-428,052,700	Cost-saving
90	10,562,000	79,200	1,360,000	-526,334,700	Cost-saving

Table 2, continued.

Parameter / Value	SARS-CoV-2 infections averted, compared with no vaccination	COVID-19 deaths averted, compared with no vaccination	Years-of-life saved, compared with no vaccination	Change in health care costs, compared with no vaccination, USD	ICER, compared with no vaccination, USD per YLS ^a
Vaccination cost per person, USD					
9	10,427,000	74,600	1,299,100	-656,846,300	Cost-saving
14.81 (base case)	10,427,000	74,600	1,299,100	-428,052,700	Cost-saving
25	10,427,000	74,600	1,299,100	-26,778,000	Cost-saving
26	10,427,000	74,600	1,299,100	12,601,200	10
35	10,427,000	74,600	1,299,100	367,014,600	280
45	10,427,000	74,600	1,299,100	760,807,300	590
75	10,427,000	74,600	1,299,100	1,942,185,200	1,500
R _e					
1.1	2,640,400	6,600	98,000	299,493,000	3,050
1.4 (base case)	10,427,000	74,600	1,299,100	-428,052,700	Cost-saving
1.8	5,955,700	110,500	1,957,700	129,359,500	70
Two-wave epidemic ^e	13,696,300	62,700	1,072,500	-682,063,700	Cost-saving
Prior immunity to SARS-CoV-2, % of population					
10	8,025,900	147,200	2,581,000	85,889,700	30
20	9,087,700	119,000	2,168,000	55,790,700	30
30 (base case)	10,427,000	74,600	1,299,100	-428,052,700	Cost-saving
40	7,127,300	18,000	279,500	-252,757,900	Cost-saving
50	608,300	1,500	24,300	545,399,700	22,460
Initial prevalence of active COVID-19, % of population					
0.05% ^f	12,247,900	70,300	1,269,000	-557,621,500	Cost-saving
0.1% (base case)	10,427,000	74,600	1,299,100	-428,052,700	Cost-saving
0.2%	8,403,300	72,300	1,288,700	-180,874,600	Cost-saving
0.5%	6,028,800	64,100	1,119,800	51,633,800	50

586 USD: United States dollars. ICER: incremental cost-effectiveness ratio. YLS: year-of-life saved. R_e:
 587 effective reproduction number.
 588

589 ^aIn these scenario analyses, the reference vaccination program (67% supply, 150,000 vaccinations per
590 day) is compared with no vaccination program under different scenarios. Displayed life-years and costs
591 are rounded to the nearest hundred, while ICERs are calculated based on non-rounded life-years and
592 costs and then rounded to the nearest ten. Cost-saving reflects more years-of-life (greater clinical
593 benefit) and lower costs, and therefore ICERs are not displayed.
594

595 ^bIn the scenario analysis of a vaccine with 75% effectiveness in preventing SARS-CoV-2 infection, the
596 effectiveness in preventing mild/moderate COVID-19 disease was adjusted to avoid a scenario in which a
597 vaccine has higher effectiveness in preventing infection than it does in preventing symptomatic disease.
598

599 ^cVaccine effectiveness in preventing mild/moderate COVID-19 (apart from severe/critical disease) has
600 minimal impact on the number of deaths. Therefore, seemingly counterintuitive results are due to
601 stochastic variability in the microsimulation. In the analysis of a vaccine that is 29% effective in
602 preventing mild/moderate COVID-19, the vaccine effectiveness in preventing SARS-CoV-2 infection was
603 adjusted to avoid a scenario in which a vaccine is more effective in preventing infection than in
604 preventing symptomatic disease.
605

606 ^dVaccine effectiveness in preventing severe/critical COVID-19 itself has minimal impact on transmission
607 and the number of infections. Therefore, seemingly counterintuitive results are due to stochastic
608 variability in the microsimulation. In the analysis of a vaccine that is 40% effective in preventing severe
609 COVID-19 requiring hospitalization, the vaccine effectiveness in preventing mild/moderate COVID-19
610 was adjusted to avoid a scenario in which a vaccine is more effective in preventing symptomatic disease
611 than in preventing severe disease requiring hospitalization.
612

613 ^eIn the analysis of an epidemic with periodic surges, the basic reproduction number (R_0) alternates
614 between low and high values over time, and the R_e changes day-to-day as the epidemic and vaccination
615 program progress and there are fewer susceptible individuals. For most of the simulation horizon, R_0 is
616 1.6 (equivalent to an initial R_e of 1.1). However, during days 90-150 and 240-300 of the simulation, R_0 is
617 increased to 2.6. This results in two epidemic waves with peak R_e of approximately 1.4-1.5.
618

619 ^fWhen the initial prevalence of active SARS-CoV-2 infection is 0.05% the epidemic peak occurs more
620 than 180 days into the simulation. Because our modeled time horizon only considers outcomes
621 occurring through day 360, delaying the epidemic peak leads to a small decrease in the number of
622 infections and deaths that are recorded in the scenario without vaccines. As a result, the absolute
623 number of deaths prevented by vaccination decreases slightly as initial prevalence of active infection is
624 changed from 0.1% to 0.05%, even though a greater proportion of deaths are prevented.

625 **Table 3. Input parameters for a model-based analysis of COVID-19 vaccination in South Africa.**

Parameter	Base case value (Range)	Sources
Initial state		
Age distribution, %		43
<20 years	37	
20-59 years	54	
≥60 years	9	
Initial health state distribution, %		
Susceptible	69.9 (49.9-89.9)	Assumption
Infected with SARS-CoV-2	0.1 (0.05 -0.5)	Assumption ^a
Recovered (prior immunity)	30 (10-50)	15,44-46
Transmission dynamics		
Effective reproduction number, R_e	1.4 (1.1-1.8)	49
Time to start of epidemic wave, days	0 (0-90)	Assumption
Relative reduction in onward transmission rate among vaccinated individuals, %	0 (0-50)	Assumption
Hospital and ICU care		
Resource availabilities		
Hospital beds, daily, n	119,400	50
ICU beds, daily, n	3,300	50
Costs		
Hospitalization, daily, USD	154 (77-309)	52-55
ICU care ^b , daily, USD	1,751 (798-3,502)	53-56
Vaccination program strategies		
Vaccine supply, % of population	67 (20-80)	16
Vaccinations per day, n	150,000 (150,000-300,000)	17,18
Time to rollout start, days	0 (0-60)	Assumption
Vaccine characteristics^c		
Effectiveness in preventing SARS-CoV-2 infection, %	40 (20-75)	Assumption
Effectiveness in preventing mild/moderate COVID-19 disease ^d , %	51 (29-79)	Age-dependent assumptions, ⁴
Effectiveness in preventing severe or critical COVID-19 disease requiring hospitalization, %	86 (40-98)	4
Number of doses required for effectiveness	1	4
Time to effectiveness, days post-vaccination	14	4
Vaccine uptake among those eligible, %	67 (50-90)	48
Vaccination cost per person, USD	14.81 (9-75)	21-23,54,55

626 R_e : effective reproduction number. ICU: intensive care unit. USD: United States dollars.

627
628 Ranges reflect values examined in analyses of alternative vaccination program strategies and in
629 sensitivity analyses of different vaccine characteristics and epidemic growth scenarios.

630
631 ^aInitial prevalence of each state of infection and disease are in Supplementary Table 5.

632

633 ^bThe range of ICU care costs includes the cost (from Edoaka et al.⁵³) applied in a repeat of several of the
634 main analyses.

635




636 ^cIn the base case, we model a vaccination program based on characteristics of the Johnson &
637 Johnson/Janssen Ad26.COVS vaccine.⁴ In sensitivity analyses, vaccine effectiveness and cost are varied
638 across a range of possible values to evaluate the influence of these parameters on clinical and economic
639 outcomes and to account for uncertainty around published estimates.

640

641 ^dValues reflect the weighted average of vaccine effectiveness in preventing mild/moderate COVID-19
642 across age groups. Our modeled vaccine effectiveness in preventing mild/moderate COVID-19 was
643 specified in an age-dependent manner to reflect the reported efficacy of the Ad26.COVS vaccine in
644 preventing moderate to severe/critical COVID-19 in South Africa.⁴ In the base case, this results in 52%
645 effectiveness in preventing any symptomatic COVID-19 across all age groups. In sensitivity analysis, this
646 value is varied from 30% to 79%.

647 **Figure 1. One-way sensitivity analysis, influence of each parameter on cumulative SARS-CoV-2**
648 **infections, COVID-19 deaths, and health care costs.** This tornado diagram demonstrates the relative
649 influence of varying each key model parameter on clinical and economic outcomes over 360 days. This is
650 intended to reflect the different scenarios in which a reference vaccination program (vaccine supply
651 sufficient for 67% of South Africa’s population, pace 150,000 vaccinations per day) might be
652 implemented. The dashed line represents the base case scenario for each parameter. Each parameter is
653 listed on the vertical axis, and in parentheses are the base case value and, after a colon, the range
654 examined. The number on the left of the range represents the left-most part of the corresponding bar,
655 and the number on the right of the range represents the right-most part of the corresponding bar. The
656 horizontal axis shows the following outcomes of a reference vaccination program: (a) cumulative SARS-
657 CoV-2 infections; (b) cumulative COVID-19 deaths; (c) cumulative health care costs. In some analyses,
658 the lowest or highest value of an examined parameter produced a result that fell in the middle of the
659 displayed range of results, due to stochastic variability when the range of results was narrow.

660 **Figure 2. Multi-way sensitivity analysis of vaccine effectiveness against infection and vaccination cost:**
661 **incremental cost-effectiveness ratio of vaccination program compared with no vaccination.** Each box
662 in the 4x4 plot is colored according to the incremental cost-effectiveness ratio (ICER). The lightest color
663 represents scenarios in which a reference vaccination program (vaccine supply sufficient for 67% of
664 South Africa’s population, pace 150,000 vaccinations per day) is cost-saving compared with no
665 vaccination program, meaning that it results in clinical benefit and reduces overall health care costs. The
666 darker colors reflect increasing ICERs, whereby a reference vaccination program, compared with no
667 vaccination program, results in both clinical benefit and higher overall health care costs. The ICER is the
668 model-generated difference in costs divided by the difference in years-of-life between a reference
669 vaccination program and no vaccination program. In none of these scenarios is the ICER above
670 \$2,000/year-of-life saved (YLS).
671
672

a**Infections****b****Deaths****c****Costs**

Incremental cost-effectiveness ratio vs no vaccination

